Uniqure NV (QURE) Sees Large Decline in Short Interest

Uniqure NV (NASDAQ:QURE) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,753,730 shares, a decline of 29.1% from the February 15th total of 2,473,269 shares. Currently, 8.4% of the company’s stock are sold short. Based on an average trading volume of 923,123 shares, the days-to-cover ratio is presently 1.9 days.

QURE has been the topic of several recent analyst reports. Wells Fargo & Co boosted their price target on Uniqure from $65.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday. BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. B. Riley initiated coverage on Uniqure in a research note on Monday, December 31st. They issued a “buy” rating and a $72.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $73.00 price target (up previously from $60.00) on shares of Uniqure in a research note on Monday, February 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $68.00 price target on shares of Uniqure in a research note on Friday, February 8th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $68.70.

QURE opened at $63.35 on Friday. The firm has a market capitalization of $2.44 billion, a PE ratio of -27.07 and a beta of 1.07. Uniqure has a 12-month low of $20.29 and a 12-month high of $67.93. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.20.

Uniqure (NASDAQ:QURE) last released its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. Sell-side analysts anticipate that Uniqure will post -2.8 EPS for the current fiscal year.

In related news, CEO Matthew C. Kapusta sold 67,376 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $63.96, for a total value of $4,309,368.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Christian Klemt sold 5,739 shares of the business’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $27.91, for a total value of $160,175.49. Following the completion of the transaction, the insider now owns 40,000 shares in the company, valued at approximately $1,116,400. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,390 shares of company stock worth $5,764,148. Insiders own 1.56% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Uniqure by 264.2% in the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 700 shares in the last quarter. Exane Derivatives purchased a new stake in shares of Uniqure in the fourth quarter valued at $41,000. Advisor Group Inc. lifted its holdings in shares of Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares in the last quarter. HRT Financial LLC purchased a new stake in shares of Uniqure in the fourth quarter valued at $289,000. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Uniqure in the fourth quarter valued at $310,000. Institutional investors own 61.16% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2019/03/17/uniqure-nv-qure-sees-large-decline-in-short-interest.html.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.